Expert Review of Clinical Immunology最新文献

Immune pathways, current and potential therapies in Mycosis fungoides and Sezary syndrome. 蕈样真菌病和癫痫综合征的免疫途径、目前和潜在的治疗方法。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-07-20 DOI: 10.1080/1744666X.2025.2533367

Friyana K Bhabha, Carrie Van Der Weyden, Joshua M L Casan, Belinda A Campbell, Christopher McCormack, H Miles Prince

{"title":"Immune pathways, current and potential therapies in Mycosis fungoides and Sezary syndrome.","authors":"Friyana K Bhabha, Carrie Van Der Weyden, Joshua M L Casan, Belinda A Campbell, Christopher McCormack, H Miles Prince","doi":"10.1080/1744666X.2025.2533367","DOIUrl":"10.1080/1744666X.2025.2533367","url":null,"abstract":"Introduction: Primary cutaneous T cell lymphomas (CTCL) comprise a diverse group of malignancies with distinct and variable treatment options and prognoses. Differentiating between subtypes can be challenging due to overlapping heterogeneous clinical and histopathologic features, mandating careful clinicopathologic correlation for diagnosis. Mycosis fungoides (MF) is the most common subtype, whereas the less frequent Sézary syndrome (SS) is viewed at the more aggressive end of the MF/SS spectrum. Large cell transformation (LCT) is a rare phenomenon associated with poor prognosis, arising in a subset of patients with MF/SS, although the exact etiology and molecular pathogenesis remains unclear.Areas covered: Progression of these diseases is influenced by a variety of immunologic factors. Our advancing understanding of immune pathways and tumor microenvironment may accelerate the development of targeted therapies. This review examines the immune-modulating effects of current and emerging therapeutic drugs for MF/SS. It encompasses both established clinical guidelines and emerging targeted agents currently under investigation in clinical trials.Expert opinion: The treatment landscape for CTCL, especially advanced disease, is becoming increasingly focused on immunotherapies and biologic agents. These treatments have the potential to provide patients with more effective clinical outcomes. The development of synergistic combination therapy will also be important expanding therapeutic options in patients with advanced CTCL.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-16"},"PeriodicalIF":3.9,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of nasal cytology in the diagnosis and treatment of Allergic rhinitis. 鼻细胞学在变应性鼻炎诊断和治疗中的作用。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-07-18 DOI: 10.1080/1744666X.2025.2534060

Yu Song, Xu Zhang, Jingyun Li, Luo Zhang, Yuan Zhang

{"title":"The role of nasal cytology in the diagnosis and treatment of Allergic rhinitis.","authors":"Yu Song, Xu Zhang, Jingyun Li, Luo Zhang, Yuan Zhang","doi":"10.1080/1744666X.2025.2534060","DOIUrl":"10.1080/1744666X.2025.2534060","url":null,"abstract":"Introduction: Allergic rhinitis (AR) is a common noninfectious chronic inflammatory disease of the nasal mucosa mediated by Immunoglobulin E (IgE). Currently, the diagnosis of AR mainly relies on a typical history of allergies, clinical symptoms and signs, skin prick tests, nasal provocation tests, and serum specific IgE detection. Nasal secretion cytology, as a method that directly reflects the inflammatory status in the nasal cavity, also plays a significant role in the diagnosis and treatment of AR.Areas covered: This review summarizes and discusses the role of nasal cytology in the diagnosis and treatment of AR, based on systematically selected articles from the PubMed database, with the aim of advancing this method and its clinical application.Expert opinion: Nasal cytology holds significant potential in revolutionizing the diagnosis and treatment of AR. Addressing the current challenges and limitations through standardization, validation studies, and integration of new technologies will pave the way for its widespread adoption and ultimately contribute to precision medicine.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-10"},"PeriodicalIF":3.9,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144658805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-life preliminary evidence for basophils as predictors of Tezepelumab response in severe asthma. 嗜碱性粒细胞作为严重哮喘患者tezepelumab反应预测因子的现实初步证据。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-07-01 Epub Date: 2025-06-14 DOI: 10.1080/1744666X.2025.2517157

Vitaliano Nicola Quaranta, Andrea Portacci, Ernesto Lulaj, Silvano Dragonieri, Santina Ferrulli, Flogerta Sana, Enrico Buonamico, Emanuela Resta, Giovanna Elisiana Carpagnano

{"title":"Real-life preliminary evidence for basophils as predictors of Tezepelumab response in severe asthma.","authors":"Vitaliano Nicola Quaranta, Andrea Portacci, Ernesto Lulaj, Silvano Dragonieri, Santina Ferrulli, Flogerta Sana, Enrico Buonamico, Emanuela Resta, Giovanna Elisiana Carpagnano","doi":"10.1080/1744666X.2025.2517157","DOIUrl":"10.1080/1744666X.2025.2517157","url":null,"abstract":"Background: Severe asthma is a complex disease with persistent symptoms despite high-dose inhaled therapy. Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), has shown efficacy across asthma phenotypes. However, identifying early responders remains a challenge. Basophils, key players in type 2 inflammation, may serve as predictive biomarkers.Objective: We evaluated the presence of super-responder status after six months of Tezepelumab therapy and explored the predictive role of blood basophil levels.Methods: A real-life, prospective study was conducted on 16 severe asthma patients. Super-responders were defined per Upham et al.'s criteria, adapted for a six-month assessment. Clinical, functional, and inflammatory parameters, including blood basophil counts, were analyzed.Results: After six months, 62.5% of patients achieved super-responder status, with complete exacerbation elimination, reduced oral corticosteroid use, and improved asthma control. A significant logarithmic association (p = 0.019) was found between baseline basophil levels and super-responder status, indicating that higher basophil counts were associated with an increased likelihood of super-response. This finding was supported by a trend toward significance in ROC curve analysis (AUC = 0.800, p = 0.050), suggesting potential predictive value.Conclusion: Tezepelumab demonstrates early efficacy in severe asthma, and baseline blood basophil levels may represent a promising biomarker for response prediction.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"977-989"},"PeriodicalIF":3.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Potential interactions between STING pathway and the complement system in immune regulation. STING通路与补体系统在免疫调节中的潜在相互作用。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-07-01 Epub Date: 2025-06-24 DOI: 10.1080/1744666X.2025.2522264

BingXiao Zhang, Yu Chen, ChenGuang Wang, WenFeng Gou, Yiliang Li, Wenbin Hou, FuJun Zhou

{"title":"Potential interactions between STING pathway and the complement system in immune regulation.","authors":"BingXiao Zhang, Yu Chen, ChenGuang Wang, WenFeng Gou, Yiliang Li, Wenbin Hou, FuJun Zhou","doi":"10.1080/1744666X.2025.2522264","DOIUrl":"10.1080/1744666X.2025.2522264","url":null,"abstract":"Introduction: The innate immune system's complement system and cGAS-STING pathway play crucial roles in pathogen defense and immune response modulation. Complement's role in cancer is multifaceted, affecting myeloid cells and T cell activities, while intracellular complement (complosome) participates in cellular processes like metabolism and autophagy. STING's activation influences tumor dynamics through NF-κB pathway interactions, enhancing or suppressing tumor responses. The interplay between complement and cGAS-STING pathways suggests potential regulatory crosstalk affecting immune responses, warranting further investigation.Areas covered: We review the functions of the complement system and the cGAS-STING pathway in pathogen clearance and tumor development. The focus is on exploring the intricate interplay between these pathways and discussing its implications for disease pathogenesis ;(PubMed: 1983-2024).Expert opinion: Such insights into these pathways could guide therapeutic strategies targeting immune modulation in oncology and autoimmune disorders, emphasizing the need to understand their complex roles in health and disease.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"929-941"},"PeriodicalIF":3.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144324895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Psoriasis, pregnancy, and lactation: clinical implications and treatments. 牛皮癣，妊娠和哺乳期：临床意义和治疗。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-07-01 Epub Date: 2025-06-02 DOI: 10.1080/1744666X.2025.2514606

Michela D'Agostino, Luca Potestio, Matteo Megna

引用次数: 0

Update on the pathophysiology and treatment of diabetic kidney disease: a narrative review. 糖尿病肾病的病理生理和治疗进展：述评。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-07-01 Epub Date: 2025-06-17 DOI: 10.1080/1744666X.2025.2521086

Akira Mima, Atsuo Nomura, Toshinori Yasuzawa

{"title":"Update on the pathophysiology and treatment of diabetic kidney disease: a narrative review.","authors":"Akira Mima, Atsuo Nomura, Toshinori Yasuzawa","doi":"10.1080/1744666X.2025.2521086","DOIUrl":"10.1080/1744666X.2025.2521086","url":null,"abstract":"Introduction: Diabetic kidney disease (DKD) is one of the most common causes of chronic kidney disease, leading to end-stage kidney disease (ESKD), and is one of the most significant complications associated with diabetes mellitus. Furthermore, the medical costs of dialysis therapy associated with ESKD are high, and financial strain is a major problem. This review first focuses on the mechanisms of DKD progression and exacerbation, and then describes the 'DKD fantastic four,' which we advocate as the latest DKD treatment.Areas covered: In DKD, increase in the extracellular matrix of mesangial cells is attributed to transforming growth factor-β/Smad1/type 4 collagen signaling, whose effects are enhanced by angiotensin II signaling.DKD activates protein kinase C (PKC)d, leading to dephosphorylation of vascular endothelial growth factor receptor-2 and reduction of its downstream effects, thereby inducing podocyte apoptosis. PKCβ inhibits insulin receptor substrate 1/Akt/endothelial NO synthase signaling in glomerular endothelial cells.Expert opinion: Recently, sodium-glucose co-transporter 2 inhibitors have been shown to reduce the risk of progression of nephropathy. Additionally, glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptides elicit vasoactive effects, reducing the risk of DKD. Finerenone, a non-steroidal mineralocorticoid receptor antagonist, reduces the composite renal endpoint without causing severe hyperkalemia.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"921-928"},"PeriodicalIF":3.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mechanisms and therapeutic potential of epithelial-immune crosstalk in airway inflammation. 气道炎症中上皮免疫串扰的机制和治疗潜力。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-07-01 Epub Date: 2025-06-04 DOI: 10.1080/1744666X.2025.2514604

Ying Chen, Yujuan Yang, Huifang Liu, Yan Hao, Xinjun Xu, Yu Zhang, Hongfei Zhao, Ting Zuo, Hang Yu, Jiali Yin, Xicheng Song

{"title":"Mechanisms and therapeutic potential of epithelial-immune crosstalk in airway inflammation.","authors":"Ying Chen, Yujuan Yang, Huifang Liu, Yan Hao, Xinjun Xu, Yu Zhang, Hongfei Zhao, Ting Zuo, Hang Yu, Jiali Yin, Xicheng Song","doi":"10.1080/1744666X.2025.2514604","DOIUrl":"10.1080/1744666X.2025.2514604","url":null,"abstract":"Introduction: Chronic airway inflammatory diseases mainly comprise chronic rhinosinusitis (CRS), allergic rhinitis (AR), asthma, cystic fibrosis (CF), and chronic obstructive pulmonary disease (COPD). Epithelial cells fulfill a protective role as a barrier; however, when stimulated, these cells also release a variety of cytokines that attract and activate immune cells, including macrophages, neutrophils, and T-lymphocytes. Excessive activation and aggregation of immune cells disrupts the balance of the cellular microenvironment, and leads to impaired immune defense of the airway mucosa, which can further exacerbate an inflammatory response.Areas covered: In this article, we discuss the key cytokines and immune pathways involved in epithelial-immune cell interactions, and we detail discoveries in the emerging field of single-cell sequencing and summarize monoclonal antibody-targeted therapies. A comprehensive search was conducted using the search terms 'epithelial cell,' 'immune,' 'interaction,' 'cytokines,' 'asthma,' 'chronic sinusitis,' 'allergic rhinitis,' 'monoclonal antibodies,' and 'single-cell sequencing' by querying Google Scholar and PubMed.Expert opinion: The intricate pathophysiology of airway inflammation remains to be fully elucidated. Emerging technologies, such as single-cell sequencing, have led to a more comprehensive characterization of the immune mechanisms underlying the pathophysiology of airway inflammatory diseases, which points the way to further precision medicine in the future.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"893-907"},"PeriodicalIF":3.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unmet needs in the management of giant cell arteritis and polymyalgia rheumatica. 巨细胞动脉炎和风湿性多肌痛治疗的未满足需求。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-07-01 Epub Date: 2025-06-18 DOI: 10.1080/1744666X.2025.2521088

Santos Castañeda, Ana Triguero-Martínez, Miren Uriarte-Ecenarro, Marisa Pardines-Ortiz, Paz Floranes, Esther F Vicente-Rabaneda, Miguel A González-Gay

引用次数: 0

Metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease: prevalence, risk factors, pathophysiological pathways and clinical consequences. 炎症性肠病中代谢功能障碍相关的脂肪变性肝病：患病率、危险因素、病理生理途径和临床后果

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-07-01 Epub Date: 2025-06-16 DOI: 10.1080/1744666X.2025.2514605

Elena Grueso Navarro, Alfredo J Lucendo

{"title":"Metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease: prevalence, risk factors, pathophysiological pathways and clinical consequences.","authors":"Elena Grueso Navarro, Alfredo J Lucendo","doi":"10.1080/1744666X.2025.2514605","DOIUrl":"10.1080/1744666X.2025.2514605","url":null,"abstract":"Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver comorbidity in patients with inflammatory bowel disease (IBD).Areas covered: This paper outlines common pathophysiological aspects related to MASLD and IBD; describes the epidemiological clues associated with both diseases; analyzes risk factors contributing to MASLD appearance and progression in IBD patients; reviews data on clinical consequences for this population; and provides advice on the management of patients with both conditions.Expert opinion: IBD itself, especially Crohn's disease, is a risk factor for MASLD and its progression to liver cirrhosis, independent of other cardiometabolic risk factors. Intestine-dependent mechanisms which contribute to MASLD in IBD and interplay with classic metabolic factors include sarcopenia, disease phenotype, duration, and activity. Changes in microbiota also contribute to deregulating the gut-liver axis in these conditions. By contrast, IBD therapies do not seem to play a relevant role in the risk of developing MASLD; and the potential of biologics and novel small molecules on liver changes requires further investigation. MASLD increases comorbidities, impairs clinical outcomes, and increases mortality in IBD patients; therefore, early detection of MASLD is a priority in IBD populations. Individualized and integrative management of both MASLD and IBD is required to improve results.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"875-891"},"PeriodicalIF":3.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chronic obstructive pulmonary disease, biological agents and small molecules: where do we stand? 慢性阻塞性肺疾病，生物制剂和小分子：我们站在哪里？

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-07-01 Epub Date: 2025-06-19 DOI: 10.1080/1744666X.2025.2522266

Carlo Lombardi, Francesco Menzella

{"title":"Chronic obstructive pulmonary disease, biological agents and small molecules: where do we stand?","authors":"Carlo Lombardi, Francesco Menzella","doi":"10.1080/1744666X.2025.2522266","DOIUrl":"10.1080/1744666X.2025.2522266","url":null,"abstract":"Introduction: Chronic Obstructive Pulmonary Disease (COPD) is characterized by persistent respiratory symptoms and airflow limitation. A subset of patients exhibits eosinophilic inflammation, which has been shown to impact disease severity and exacerbation frequency.Areas covered: This review aims to provide an update on the role of eosinophils in COPD and the efficacy of biologics targeting inflammation. Furthermore, we will explore eosinophilia as a biomarker for COPD outcomes. The findings highlight the potential of biologics in managing COPD. We conducted a review of the English-language literature from the beginning of the databases reviewed through April 2025.Expert opinion: In COPD there is a close interplay between inflammation, lung damage and multimorbidities, mechanisms that determine a lower efficacy of biologics. Patients currently eligible for biologics are only the subpopulation with eosinophilic airway inflammation, but biologics that target broad-acting epithelial cytokines might have a greater efficacy in a complex disease such as COPD. This is because their mechanism of action is not limited to modulation of eosinophilic inflammation alone but to multiple driver pathways. Looking forward, there is an urgent need to identify new biomarkers for better patient selection to improve the impact of biologics, which is still not yet fully satisfactory.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"909-919"},"PeriodicalIF":3.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0